Illumina, Inc stock page - price, fundamentals, dividends - iOCharts

ILMN

412.01
-5.18 (-1.24%)
Illumina, Inc (NASDAQ, USD)
Healthcare >
Diagnostics & Research
Market cap
60.15B
Ent value
59.55B
Price/Sales
10.89
Price/Book
12.22
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
57.02
Forward P/E
57.22
PEG
4.19
EPS growth
23.20%
1 year return
28.06%
3 year return
11.39%
5 year return
24.42%
10 year return
31.18%
Last updated: 2021-10-27

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open419.28
Daily high420.52
Daily low411.07
Daily Volume665K
All-time high524.84
1y analyst estimate410.18
Beta0.94
EPS (TTM)7.23
Dividend per share-
Ex-div date-
Next earnings date28 Oct 2021

Downside potential

Loading...
Downside potential data
ILMNS&P500
Current price drop from All-time high-21.50%-0.44%
Highest price drop-96.14%-56.47%
Date of highest drop13 Mar 20039 Mar 2009
Avg drop from high-34.61%-11.44%
Avg time to new high23 days12 days
Max time to new high1731 days1805 days

DIVIDENDS

ILMN does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E57.02
Price to OCF34.30
Price to FCF41.83
Price to EBITDA35.41
EV to EBITDA35.05

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales10.89
Price to Book12.22
EV to Sales10.78

FINANCIALS

Per share

Loading...
Per share data
Current share count146.00M
EPS (TTM)7.23
FCF per share (TTM)9.85

Income statement

Loading...
Income statement data
Revenue (TTM)5.53B
Gross profit (TTM)3.52B
Operating income (TTM)1.03B
Net income (TTM)1.05B
EPS (TTM)7.23
EPS (1y forward)7.20

Margins

Loading...
Margins data
Gross margin (TTM)63.62%
Operating margin (TTM)18.59%
Profit margin (TTM)19.09%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash4.43B
Net receivables517.00M
Total current assets5.64B
Goodwill897.00M
Intangible assets134.00M
Property, plant and equipment1.44B
Total assets8.76B
Accounts payable780.00M
Short/Current long term debt2.16B
Total current liabilities1.27B
Total liabilities3.83B
Shareholder's equity4.92B
Net tangible assets4.55B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)1.75B
Capital expenditures (TTM)316.00M
Free cash flow (TTM)1.44B
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity22.48%
Return on Assets13.91%
Return on Invested Capital17.47%
Cash Return on Invested Capital23.81%
COMPANY DETAILS
ILMN (Illumina, Inc) company logo
Marketcap
60.15B
Marketcap category
Large-cap
Description
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Employees
7800
SEC filings
CEO
Francis deSouza
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Whole-genome sequencing (WGS) enables faster identification of disease-causing genetic abnormalities in infants improving clinical care and management
October 28, 2021
Polen Capital, an investment management firm, published its “Polen Focus Growth” third quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly gross return of 2.78% was deli...
October 26, 2021
Zacks.com featured highlights include: Stoneridge, Illumina, TPI Composites and JD.com
October 22, 2021
SAN DIEGO, October 21, 2021 /3BL Media/ -- Illumina, Inc. (NASDAQ:ILMN) announced that it will host its first Environment, Social and Corporate Governance (ESG) focused investor event at 11:00 am P...
October 21, 2021
Steer clear of toxic stocks like SRI, ILMN, TPIC and JD to safeguard your portfolio from losses.
October 21, 2021
ACCD, EAT, ILMN, MAXN, and TM have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2021
October 19, 2021
In this article, we will take a look at the 11 best genomic stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Genomic Stocks to Buy Now. Genomics is a...
October 19, 2021
Leading developer of life science tools joins an innovative group of Power100 Champions, leading the region to a sustainable future
October 18, 2021
Ensemble Capital, an investment management firm, published its third-quarter 2021 investor letter – a copy of which can be downloaded here. In the letter, the fund discussed why they see so much new v...
October 18, 2021
Next page